EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clonal dynamics of chronic myelomonocytic leukemia progression: paired‐sample comparison

Hsiao-Wen Kao, Ming-Chung Kuo, Che-Wei Ou, Ting-Yu Huang, Hung Chang, Tung-Liang Lin, Yu-Shin Hung, Jin-Hou Wu, Lee-Yung Shih iD

The Journal of Pathology · 2025-04 · 265 (4) · 437-447

DOI: 10.1002/path.6396 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Pathology, online erschienen am 05.02.2025. Verfasst von Hsiao-Wen Kao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, Mutation, Clonal Evolution, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: the Ministry of Health and Welfare, National Health Research Institutes, Chang Gung Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated the clonal evolution of chronic myelomonocytic leukemia (CMML) progression to secondary acute myeloid leukemia (sAML) by next‐generation sequencing and pyrosequencing for variant allele frequency (VAF) of gene mutations and SNP microarray for copy neutral loss of heterozygosity (CN‐LOH) in 38 paired samples from CMML/sAML patients of Taiwanese origin. The median interval between CMML and sAML samples collection was 14.9 months (1.0–89.6). RUNX1 (57%), TET2 (46%), SRSF2 (37%), and ASXL1 (28%) mutations were frequent at CMML diagnosis. Baseline VAF in epigenetic regulator genes was high (>35%) in 83% of mutational events at the CMML phase, remained stable in 78% (VAF changes 10%) during progression to sAML. Transcription factor genes showed high VAF (>35%) in 51% at the CMML phase, and stable VAF in 60% during progression. VAF of spliceosome genes was high (>35%) in 70% at CMML phase, and stable in 61% during progression. Activated signaling genes exhibited acquisition or loss during progression. TET2 mutations were often founding clones, and SRSF2 , ASXL1 , DNMT3A , EZH2 , or spliceosome genes also acted as ancestral mutations. RUNX1 mutations were typically later events and occasionally ancestral hits or germline mutations. Acquisition of cytogenetic changes, signaling pathways genes ( PTPN11 , FLT3 , NRAS , CBL ), or AML‐defined genes ( NPM1 , CEBPA , CBFB :: MYH11 ) by linear or branching evolution occurred during sAML progression. CN‐LOH was noted in EZH2 , CBL , TET2 , and DNMT3A genes. CEBPA mutation and concurrent biallelic TET2 with NRAS mutations at CMML diagnosis were risk factors for time to AML progression and overall survival. A characteristic ASXL1 MT / RUNX1 MT /Spliceosome MT /signaling WT genetic profile was associated with monocyte counts of 0.5–1.0 × 10 9 /l. This study highlights the complexity and heterogeneity of dynamic changes in clonal architecture during CMML progression, emphasizing its importance in pathogenesis, phenotype, risk stratification, and therapeutic strategy. © 2025 The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicMutationClonal EvolutionLeukemia, Myeloid, AcuteBiomarkers, TumorHumansMaleFemaleAgedDisease ProgressionMiddle AgedAged, 80 and overLoss of HeterozygosityHigh-Throughput Nucleotide SequencingCore Binding Factor Alpha 2 SubunitPolymorphism, Single NucleotideAdultTaiwanGene FrequencyGenetic Predisposition to DiseaseDNA-Binding ProteinsDioxygenases

Stichwörter der Autor:innen

acute myeloid leukemiaallele frequencychronic myelomonocytic leukemiaclonal evolutionnext‐generation sequencingpaired‐sample analyses

Substanzen

TET2 protein, humanCore Binding Factor Alpha 2 SubunitBiomarkers, TumorRUNX1 protein, humanDNA-Binding ProteinsDioxygenases

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.

ORCID-Profile: Lee-Yung Shih

Förderung

  • the Ministry of Health and Welfare
  • National Health Research Institutes
  • Chang Gung Memorial Hospital

Zitieren

APA

Kao, H. W., Kuo, M. C., Ou, C. W., Huang, T. Y., Chang, H., Lin, T. L., Hung, Y. S., Wu, J. H., & Shih, L. Y. (2025). Clonal dynamics of chronic myelomonocytic leukemia progression: paired‐sample comparison. The Journal of Pathology, 265(4), 437-447. https://doi.org/10.1002/path.6396

Vancouver

Kao HW, Kuo MC, Ou CW, Huang TY, Chang H, Lin TL, et al. Clonal dynamics of chronic myelomonocytic leukemia progression: paired‐sample comparison. The Journal of Pathology. 2025;265(4):437-447. doi:10.1002/path.6396

BibTeX
@article{Kao2025,
  author = {Kao, Hsiao-Wen and Kuo, Ming-Chung and Ou, Che-Wei and Huang, Ting-Yu and Chang, Hung and Lin, Tung-Liang and Hung, Yu-Shin and Wu, Jin-Hou and Shih, Lee-Yung},
  title = {Clonal dynamics of chronic myelomonocytic leukemia progression: paired‐sample comparison},
  journal = {The Journal of Pathology},
  year = {2025},
  volume = {265},
  number = {4},
  pages = {437--447},
  doi = {10.1002/path.6396}
}
Kostenlos starten →